Proton spectroscopy provides accurate pathology on biopsy and in vivo

Journal of Magnetic Resonance Imaging

Volumn 24, Issue 3, 2006, Pages 459-477

  Mountford, Carolyn ^a,c   Lean, Cynthia ^a   Malycha, Peter ^b   Russell, Peter ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Biopsy; Body; In vivo; Pathology; Spectroscopy

Indexed keywords

BARRETT ESOPHAGUS; BREAST BIOPSY; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; LABORATORY DIAGNOSIS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE DISEASE; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; THYROID ADENOMA;

ADENOCARCINOMA; BIOPSY; BREAST NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASMS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; THYROID NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 33748285258     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.20668     Document Type: Review

References (102)

1. Mountford C, Doran S, Lean C, Russell P. Proton MRS can determine the pathology of human cancers with a high level of accuracy. Chem Rev 2004;104:3677-3704.
2. Swindle P, McCredie S, Russell P, et al. Pathologic characterization of human prostate tissue with proton magnetic resonance spectroscopy. Radiology 2003;228:144-151.
3. Ross B, Danielsen E. Magnetic resonance spectroscopy: diagnosis of neurological diseases. New York: Marcel Dekker; 1999.
4. Block RE. Factors affecting proton magnetic resonance linewidths of water in several rat tissues. FEBS Lett 1973;34:109-112.
5. Daniels A, Williams R, Wright P. The character of the stored molecules in chromaffin granules of the adrenal medulla: a nuclear magnetic resonance study. Neuroscience 1978;3:573-585.
6. Metcalf D. The thymus: its role in immune responses, leukaemia development and carcinogenesis. Recent Results Cancer Res 1966:5-11.
7. Mountford CE, Grossman G, Gatenby PA, Fox RM. High-resolution proton nuclear magnetic resonance: application to the study of leukaemic lymphocytes. Br J Cancer 1980;41:1000-1003.
8. Mountford CE, Grossman G, Hampson AW, Holmes KT. Influenza virus: an NMR study of mechanisms involved in infection. Biochim Biophys Acta 1982;720:65-74.
9. Ramshaw IA, Carlsen ST, Hoon D, Warrington C. A 6-thioguanine-resistant variant of the 13762 cell line which is no longer tumorigenic or metastatic. Int J Cancer 1982;30:601-607.
10. Mountford CE, Wright LC, Holmes KT, Mackinnon WB, Gregory P, Fox RM. High-resolution proton nuclear magnetic resonance analysis of metastatic cancer cells. Science 1984;226:1415-1418.
11. Mountford C, Russell P. 1994. Method and apparatus for determining chemical states of living animal or human tissue using nuclear magnetic resonance. U.S. Patent 5318031.
12. Mountford C. Russell P, Smith I. Somorjai R. 2000. US PCT Patent application for magnetic resonance spectroscopy of breast biopsy to determine pathology, vascularisation and nodal involvement. PCT Appln. No PCT/CA00/01238, filed October 18, 2000, claiming priority on US Provisional Application S.N. 60/160, 029.
13. Ernst RR, Anderson WA. Application of Fourier transform techniques to magnetic resonance spectroscopy. Rev Sci Instrum 1966;37:93-103.
14. Cross KJ, Holmes KT, Mountford CE, Wright PE. Assignment of acyl chain resonances from membranes of mammalian cells by two-dimensional NMR methods. Biochemistry 1984;23:5895-5897.
15. Delikatny E, Hull W, Mountford C. The effect of altering time domains and window functions in two-dimensional proton COSY spectra of biological specimens. J Magn Res 1991;94:563-573.
16. Lean CL, Somorjai RL, Smith ICP, Russell P, Mountford CE. Accurate diagnosis and prognosis of human cancers by proton MRS and a three stage classification strategy. In: Webb G. editor. Annual reports on NMR spectroscopy. Burlington, MA: Academic Press; 2002. p 71-111.
17. Delikatny EJ, Russell P, Hunter JC, et al. Proton MR and human cervical neoplasia 1: ex vivo spectroscopy allows distinction of invasive carcinoma of the cervix from carcinoma in situ and other preinvasive lesions. Radiology 1993;188:791-796.
18. Mazzaferri E. Management of a solitary thyroid nodule. N Engl J Med 1993;328:553-559.
19. Doran S, Falk G, Somorjai R, et al. Pathology of Barrett's oesophagus by proton magnetic resonance spectroscopy and a statistical classification strategy. Am J Surg 2003;185:232-238.
20. Mountford CE, Lean CL, Mackinnon WB, Russell P. The use of proton MR in cancer pathology. In: Webb GA, editor. Annual reports on NMR spectroscopy. Burlington, MA: Academic Press; 1993. p 173-215.
21. Lean CL, Mackinnon WB, Delikatny EJ, Whitehead RH, Mountford CE. Cell-surface fucosylation and magnetic resonance spectroscopy characterization of human malignant colorectal cells. Biochemistry 1992;31:11095-11105.
22. Mackinnon WB, Huschtscha L, Dent K, Hancock R, Paraskeva C, Mountford CE. Correlation of cellular differentiation in human colorectal carcinoma and adenoma cell lines with metabolite profiles determined by 1H magnetic resonance spectroscopy. Int J Cancer 1994;59:248-261.
23. Mackinnon WB, Russell P, May GL, Mountford CE. Characterisation of human ovarian epithelial tumours (ex vivo) by proton magnetic resonance spectroscopy. Int J Gynaecol Cancer 1995;5:211-221.
24. Mackinnon WB, Delbridge L, Russell P, et al. Two-dimensional proton magnetic resonance spectroscopy for tissue characterization of thyroid neoplasms. World J Surg 1996;20:841-847.
25. Rutter A, Mackinnon WB, Huschtscha LI, Mountford CE. A proton magnetic resonance spectroscopy study of aging and transformed human flbroblasts. Exp Gerontol 1996;31:669-686.
26. Mountford CE, Delikatny EJ, Dyne M, et al. Uterine cervical punch biopsy specimens can be analyzed by 1H MRS. Magn Reson Med 1990;13:324-331.
27. Lean CL, Newland RC, Ende DA, Bokey EL, Smith IC, Mountford CE. Assessment of human colorectal biopsies by 1H MRS: correlation with histopathology. Magn Reson Med 1993;30:525-533.
28. Russell P, Lean CL, Delbridge L, May GL, Dowd S, Mountford CE. Proton magnetic resonance and human thyroid neoplasia. I: Discrimination between benign and malignant neoplasms. Am J Med 1994;96:383-388.
29. Delbridge L. Lean C, Russell P, et al. Proton magnetic resonance and human thyroid neoplasms: potential avoidance of surgery for benign follicular neoplasms. World J Surg 1994;18:512-517.
30. Delbridge L, Lean CL, Russell P, et al. Proton magnetic resonance and human thyroid neoplasia. II: Potential avoidance of surgery for benign follicular neoplasms. World J Surg 1994;18:512-516; discussion 516-517.
31. Lean CL, Delbridge L, Russell P, et al. Diagnosis of follicular thyroid lesions by proton magnetic resonance on fine needle biopsy. J Clin Endocrinol Metab 1995;80:1306-1311.
32. 1H MRS in detecting early malignant changes? In: Giuli R. editor. The oesophagrogastric junction: 420 questions. 420 answers. Montrouge. France: J. Libbey Eurotext; 1998. p 1122-1127.
33. Mackinnon WB, Barry PA, Malycha PL, et al. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology 1997;204:661-666.
34. Mountford CE. Breast cancer and magnetic resonance spectroscopy. Todays Life Sci 1998:22-25.
35. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Research 1999;59:80-84.
36. Barzilai A, Horowitz A, Geier A, Degani H. Phosphate metabolites and steroid hormone receptors of benign and malignant breast tumors. A nuclear magnetic resonance study. Cancer 1991;67:2919-2925.
37. Listinsky JJ, Siegal GP, Listinsky CM. Alpha-L-fucose: a potentially critical molecule in pathologic processes including neoplasia. Am J Clin Pathol 1998;110:425-440.
38. Listinsky JJ, Listinsky CM, Alapati V, Siegal GP. Cell surface fucose ablation as a therapeutic strategy for malignant neoplasms. Adv Anat Pathol 2001;8:330-337.
39. van der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA 2000;10:153-159.
40. Hahn P, Smith ICP, Leboldus L, Littman C, Somorjai RL, Bezabeh T. The classification of benign and malignant human prostate tissue by multivariate analysis of H-1 magnetic resonance spectra. Cancer Res 1997;57:3398-3401.
41. Hull WE. Computerized shimming with the simplex algorithm. In: Bruker Spin Report. # 154. Billerica, MA: Bruker BioSpin: 2003. p 15-17.
42. Hull WE. Computerized shimming with the tuning algorithm. In: Bruker Spin Report. # 152. Billerica, MA: Bruker BioSpin; 2003. p 53-61.
43. Ernst R, Bodenhausen G, Wokaun A. Principles of nuclear magnetic resonance in one and two dimensions. Oxford: Clarendon Press, 1987.
44. Smith J, Kwock L. Castillo M. Effects of contrast material on single-volume proton MR spectroscopy. AJNR Am J Neuroradiol 2000;21:1084-1089.
45. Somorjai R, Alexander M, Baumgartner R, et al. A data-driven, flexible machine learning strategy for the classification of biomedical data. In: Dubitzky W, Azuaje F, editors. Artificial intelligence methods and tools for systems biology. Computational biology, vol. 5. Dordrecht: Springer; 2004.
46. Cole P, Rodu B. Descriptive epidemiology: cancer statistics. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer. Principles and practice of oncology. Philadelphia: Lippincot Williams and Wilkins; 2001. p 228-241.
47. Mountford CE, Somorjai RL, Malycha P, et al. Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy. Br J Surg 2001;88:1234-1240.
48. Lean CL, Russell P, Mountford CE. Magnetic resonance spectroscopy: a new gold standard for medical diagnosis. J Womens Imaging 2000;2:19-30.
49. Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed 2002;15:327-337.
50. Snead DR, Vryenhoef, P, Finder SE, et al. Routine audit of breast fine needle aspiration (FNA) cytology specimens and aspirator inadequate rates. Cytopathology 1997;8:236-247.
51. Katz-Brull R, Lavin P, Lenkinski R. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 2002;94:1197-1203.
52. Gribbestad IS, Singstad TE, Nilsen G, et al. In vivo 1H MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging 1998;8:1191-1197.
53. Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: characterization with proton MR spectroscopy. Radiology 1998;209:269-275.
54. Kvistad KA, Bakken IJ, Gribbestad IS, et al. Characterization of neoplastic and normal human breast tissues with in vivo 1H MR spectroscopy. J Magn Reson Imaging 1999;10:159-164.
55. Yeung DKW, Cheung HS, Tse GMK. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy-initial results. Radiology 2001;220;40-46.
56. Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE. The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat 2001;68:45-54.
57. Jagannathan NR, Kumar M, Seenu V, et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001;84:1016-1022.
58. Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Bluemke DA. Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging 2004;19:68-75.
59. Bolan PJ, Meisamy S, Baker EH, et al. In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 2003;50:1134-1143.
60. Stanwell P, Gluch L, Clark D, et al. Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5T. Eur Radiol 2005;15:1037-1043.
61. Thomas MA, Chung H-K, Middlekauff H. Localized two-dimensional 1H magnetic resonance exchange spectroscopy: a preliminary evaluation in human muscle. Magn Reson Med 2005;53;495-502.
62. Jacobs M, Barker P, Bottomley P, Bhujwalla Z, Bluemke D. Proton MR spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging 2004;19:68-75.
63. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
64. van der Hoek R. Malignant neoplasms of the prostate. In: Disease registers unit. Canberra: Australian Institute of Health and Welfare; 1995. p 40.
65. McNeal JE. Normal histology of the prostate. Am J Surg Pathol 1988;12:619-633.
66. Schnall M, Lenkinski R, Pollack H, Imai Y, Kressel H. Prostate: MR imaging with an endorectal surface coil. Radiology 1989;172:570-574.
67. Narayan P, Jajodia P, Kurhanewicz J, et al. Transrectal MR spectroscopy, a noninvasive technique using cellular metabolite ratios to differentiate normal human prostates from prostate cancer and benign hyperplasia. J Urol 1989;141:170A.
68. Narayan P, Vigneron DB, Jajodia P, et al. Transrectal probe for 1H MR1 and 31P MR spectroscopy of the prostate gland. Magn Reson Med 1989;11:209-220.
69. Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, Ruijs SH. Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn Reson Med 1997;37:204-213.
70. van der Graaf M, van den Boogert HJ, Jager GJ, Barentsz JO, Heerschap A. Human prostate: multisection proton MR spectroscopic imaging with a single spin-echo sequence-preliminary experience. Radiology 1999;213:919-925.
71. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002;16:451-463.
72. Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2000;2:166-189.
73. Fütterer J, Scheenen T, Huisman H, et al. Initial experience of 3 Tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol 2004;39:671-680.
74. Somorjai R, Bourne R. Regression analysis of denned mixtures of cancer and benign tissue in prostate biopsies. In: Proceedings of the 11th Annual Meeting of ISMRM, Toronto, Canada, 2003. p. 762.
75. 1H magnetic resonance spectroscopy of preinvasive and invasive cervical cancer: in vivo-ex vivo profiles and effect of tumor load. J Magn Reson Imaging 2004;19:356-364.
76. Mazzeferri E. Thyroid cancer in thyroid nodules: finding a needle in a haystack. Am J Med 1992;93:359-362.
77. Somorjai RL, Nikulin AE, Pizzi N, et al. Computerized consensus diagnosis: a classification strategy for the robust analysis of MR spectra. 1. Application to 1H spectra of thyroid neoplasms. Magn Reson Med 1995;33:257-263.
78. King AD, Yeung DKW, Ahuja AT, et al. In vivo 1H MR spectroscopy of thyroid carcinoma. Eur J Radiol 2005;54:112-117.
79. King SB, Ryner LN, Tomanek B, Sharp JC, Smith IC. MR spectroscopy using multi-ring surface coils. Magn Reson Med 1999;42:655-664.
80. Plante M. Fertility preservation in the management of gynecologic cancers. Curr Opin Oncol 2000;12:497-507.
81. Morice P, Wicart-Poque F, Rey A, et al. Results of conservative treatment in epithelial ovarian carcinoma. Cancer 2001;92:2412-2418.
82. Russell P, Robboy S, Anderson M. Ovarian tumours: classification and clinical perspective. London: Churchill Livingstone; 2002.
83. Diebold J, Seemuller F, Lohrs U. K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy. Lab Invest 2003;83:251-258.
84. Hauptmann S, Dietel M. Serous tumors of low malignant potential of the ovary-molecular pathology: part 2. Virchows Archiv 2001;438:539-551.
85. 1H MR spectra of biopsies from untreated and recurrent ovarian cancer using linear discriminant analysis. Magn Reson Med 1997;38:569-576.
86. Lean CL, Mackinnon WB, Mountford CE. Fucose in 1H COSY spectra of plasma membrane fragments shed from human malignant colorectal cells. Magn Reson Med 1991;20:306-311.
87. Kim Y, Yuan M, Itzkowitz S, et al. Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant and nonmalignant colonic tissues. Cancer Res 1986;46:5985-5992.
88. Abe K, Hakomori S, Ohshiba S. Differential expression of difucosyl type 2 chain (LeY) denned by monoclonal antibody AH6 in different locations of colonic epithelia, various histological types of colonic polyps, and adenocarcinomas. Cancer Res 1986;46:2639-2644.
89. Nudelman E, Levery S, Kaizu T, Hakomori S. Novel fucolipids of human adenocarcinoma: characterisation of the major Le y antigen of human adenocarcinoma as trifucosylnonaosyl LeY glycolipid (III 3 FucV 3 FucVI 2 FucnLc 6). J Biol Chem 1986;261:11247-11253.
90. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
91. Mountford CE, Stanwell P, Ferner A, et al. In vivo spectroscopy and imaging of the ovary in vivo at 3 Tesla and spectroscopy on biopsy at 8.5 Tesla. JWI 2005;7:71-76.
92. Pohl H, Welch G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-146.
93. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the oesophagus and gastric cardia. JAMA 1991;265:1287-1289.
94. Clark GW, Smyrk TC, Burdiles P, et al. Is Barrett's metaplasia the source of adenocarcinomas of the cardia? Arch Surg 1994;129:609-614.
95. Spechler S, Goyal R. Cancer surveillance in Barrett's oesophagus: what is the end point? Gastroenterology 1994;106:275-276.
96. Spechler S. Barretfs oesophagus. Semin Gastrointest Dis 1996;7:51-60.
97. Streitz AP, Andrews CW, Ellis FH. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993;105:383-387.
98. Ireland AP, Clark GW, DeMeester TR. Barren's oesophagus: the significance of p53 in clinical practice. Ann Surg 1997;225:17-30.
99. Bourne R, Dzendrowskyj T, Mountford C. Leakage of metabolites from tissue biopsies can result in large errors in quantitation by MRS. NMR Biomed 2003;16:96-101.
100. Kreis R. Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed 2004;17:361-381.
101. Nelson SJ, Vigneron DB, Dillon WP. Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. NMR Biomed 1999;12:123-138.
102. Lean C, Doran S, Somorjai R, et al. Determination of grade and receptor status from primary breast lesion by magnetic resonance spectroscopy. Technol Cancer Res Treat 2004;3:551-556.